Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06488924

An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB

Status
Recruiting
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
10 (estimated)
Sponsor
JCR Pharmaceuticals Co., Ltd. · Industry
Sex
All
Age
17 Years
Healthy volunteers
Not accepted

Summary

A Phase I/ II, open-label study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIB patients.

Conditions

Interventions

TypeNameDescription
DRUGJR-446IV infusion

Timeline

Start date
2024-11-05
Primary completion
2030-04-30
Completion
2030-04-30
First posted
2024-07-05
Last updated
2025-09-02

Locations

3 sites across 1 country: Japan

Source: ClinicalTrials.gov record NCT06488924. Inclusion in this directory is not an endorsement.

An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB (NCT06488924) · Clinical Trials Directory